piperaquine has been researched along with efavirenz in 7 studies
| Studies (piperaquine) | Trials (piperaquine) | Recent Studies (post-2010) (piperaquine) | Studies (efavirenz) | Trials (efavirenz) | Recent Studies (post-2010) (efavirenz) |
|---|---|---|---|---|---|
| 638 | 227 | 497 | 3,110 | 631 | 1,611 |
| Protein | Taxonomy | piperaquine (IC50) | efavirenz (IC50) |
|---|---|---|---|
| Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain B, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain B, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain A, Pol Polyprotein | Human immunodeficiency virus 1 | 0.2612 | |
| Chain B, Pol Polyprotein | Human immunodeficiency virus 1 | 0.2612 | |
| Prothrombin | Bos taurus (cattle) | 0.022 | |
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 0.1852 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.02 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
| Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 0.054 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.004 | |
| Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 | Human immunodeficiency virus 1 | 0.0035 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.1627 | |
| Reverse transcriptase | Human immunodeficiency virus 1 | 0.0643 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Aweeka, FT; Chamankhah, N; Dorsey, G; Havlir, D; Huang, L; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, M; Koss, CA; Mwebaza, N; Rosenthal, PJ; Ruel, T; Were, M | 1 |
| Badhan, RKS; Coleman, M; Olafuyi, O | 1 |
| Aweeka, F; Dorsey, G; Havlir, D; Huang, L; Jagannathan, P; Kakuru, A; Kamya, M; Muhindo, M; Nakalembe, M; Natureeba, P; Rosenthal, PJ; Savic, RM; Vucicevic, K; Wallender, E | 1 |
| Aweeka, FT; Jagannathan, P; Kajubi, R | 1 |
| Srinivas, NR | 1 |
| Banda, CG; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Macuacua, S; Maculuve, S; Mallewa, J; Mukaka, M; Mwapasa, V; Piqueras, M; Sevene, E; Terlouw, DJ; Vala, A | 1 |
| Allen, E; Banda, CG; Barnes, KI; Chirwa, M; Kapulula, M; Maartens, G; Madanitsa, M; Munharo, S; Muyaya, S; Mwapasa, V; Nkosi, D; Phiri, KS; Tarning, J; Ter Kuile, FO; Workman, L | 1 |
3 trial(s) available for piperaquine and efavirenz
| Article | Year |
|---|---|
Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.
Topics: Adolescent; Adult; Alkynes; Antimalarials; Area Under Curve; Artemisinins; Benzoxazines; Chemoprevention; Cyclopropanes; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Malaria; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Complications, Parasitic; Quinolines; Reverse Transcriptase Inhibitors; Uganda; Young Adult | 2017 |
Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial.
Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemisinins; Benzoxazines; Cyclopropanes; Drug Combinations; Female; Humans; Malaria, Falciparum; Malawi; Male; Middle Aged; Mozambique; Nevirapine; Plasmodium falciparum; Quinolines; Young Adult | 2019 |
Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV.
Topics: Antimalarials; Female; HIV Infections; Humans; Malaria; Pregnancy; Pregnant Women; Quinolines | 2022 |
4 other study(ies) available for piperaquine and efavirenz
| Article | Year |
|---|---|
The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy.
Topics: Alkynes; Antimalarials; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Malaria; Models, Biological; Population Groups; Pregnancy; Quinolines; Ritonavir; Serum Albumin, Human | 2017 |
Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Antimalarials; Artemisinins; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Malaria, Falciparum; Pregnancy; Pregnancy Complications, Parasitic; Quinolines; Young Adult | 2018 |
Response to "Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction".
Topics: Alkynes; Artemisinins; Benzoxazines; Chemoprevention; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; Humans; Malaria; Pregnancy; Quinolines | 2018 |
Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction.
Topics: Alkynes; Artemisinins; Benzoxazines; Chemoprevention; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; Humans; Malaria; Pregnancy; Quinolines | 2018 |